As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Biodel

  • Thursday's Range: $0.23-$0.26
  • 52-Week Range: $0.22-$1.61
  • Thursday's Volume: 1.79 million
  • Three-Month Average Volume: 1.49 million

Biodel  (BIOD) , a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the U.S. This stock traded up 6.9% to 25 cents per share in Thursday's trading session.

From a technical perspective, Biodel spiked sharply higher right above some near-term support at 22 cents per share with above-average volume. This stock has potentially carved out a major bottoming chart pattern over the last two months and change, after shares found some buying interest at 22 cents to 23 cents per share. Shares of Biodel are now starting to trend to the upside with strong volume and it's quickly moving within range of triggering a near-term breakout trade above some key overhead resistance levels. That breakout will trigger if this stock manages to take out some near-term overhead resistance levels at its 20-day moving average of 28 cents per share and its 50-day moving average of 30 cents per share with high volume.

Traders should now look for long-biased trades in Biodel as long as it's trending above some key near-term support at 22 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.49 million shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at 32 cents to 35 cents per share, or even its recent highs at 37 cents to around 38 cents per share.

Synergy Pharmaceuticals

  • Thursday's Range: $3.89-$4.48
  • 52-Week Range: $2.75-$10.15
  • Thursday's Volume: 4.78 million
  • Three-Month Average Volume: 1.86 million

Synergy Pharmaceuticals  (SGYP) , a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal disorders and diseases. This stock traded up 10.5% to $4.42 in Thursday's trading session.

From a technical perspective, Synergy Pharmaceuticals soared sharply higher on Thursday right above its recent low of $3.70 a share with monster upside volume. This high-volume rip to the upside is coming off oversold levels, since the current relative strength index reading for this stock is 34.5. Oversold can always get more oversold, but shares of Synergy Pharmaceuticals are now trending higher and it's quickly moving within range of triggering a near-term breakout trade. That trade will hit if this stock manages to take out some near-term overhead resistance at $4.50 a share with high volume.

Traders should now look for long-biased trades in Synergy Pharmaceuticals as long as it's trending above Thursday's intraday low of $3.88 a share and then once it sustains a move or close above $4.50 a share with volume that hits near or above 1.86 million shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $5 to its 20-day moving average of $5.24, or even $5.50 to its 50-day moving average of $5.78 a share.

Amicus Therapeutics

  • Thursday's Range: $6.00-$7.44
  • 52-Week Range: $5.69-$18.83
  • Thursday's Volume: 2.37 million
  • Three-Month Average Volume: 2.34 million

Amicus Therapeutics  (FOLD) , a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. This stock traded up 13.4% to $7.42 in Thursday's trading session.

From a technical perspective, Amicus Therapeutics exploded higher on Thursday right off some previous support at $6 a share with above-average volume. This stock has been downtrending badly over the last two months, with shares falling sharply off its high of $11.78 a share to its recent low of $6 a share. During that downtrend, shares of Amicus Therapeutics have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to rebound sharply off that $6 a share low, and it's now quickly moving within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to clear Thursday's intraday high of $7.44 a share and then once it takes out more key resistance at around $8 a share with high volume.

Traders should now look for long-biased trades in Amicus Therapeutics as long as it's trending above $7 a share or above $6.50 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 2.34 million shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $8.79 a share or its 50-day moving average of $9.63 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author was long BIOD.

More from Opinion

Microsoft Pops on Strong Earnings and Guidance: 8 Key Takeaways

Microsoft Pops on Strong Earnings and Guidance: 8 Key Takeaways

Bitcoin Is Up, but Traditional Investors Remain Skeptical

Bitcoin Is Up, but Traditional Investors Remain Skeptical

EBay's Soft Guidance Doesn't Reflect Well on its Attempts to Fight Off Amazon

EBay's Soft Guidance Doesn't Reflect Well on its Attempts to Fight Off Amazon

4 Key Takeaways for Apple, Nvidia and Others From TSMC's Earnings Report

4 Key Takeaways for Apple, Nvidia and Others From TSMC's Earnings Report

3 Things to Watch When Microsoft Reports Earnings

3 Things to Watch When Microsoft Reports Earnings